Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Wolfgang Hilbe
- Target Recruit Count
- 41
- Registration Number
- NCT00406302
- Locations
- 🇦🇹
University Hospital, Internal Medicine, Innsbruck, Tirol, Austria
🇦🇹OA Dr. Rainer Kolb, Wels, Austria
🇦🇹Hosptial Kufstein, Kufstein, Tirol, Austria
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00402545
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
- Conditions
- Adenocarcinoma of the ColonGastrointestinal Stromal TumorMetastatic Gastrointestinal Carcinoid TumorRecurrent Colon CancerRecurrent Esophageal CancerRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Adult Primary Liver CancerRecurrent Anal CancerRecurrent Basal Cell Carcinoma of the LipRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Interventions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00397384
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00392769
- Locations
- 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
🇺🇸New York Presbyterian Hospital-Cornell Medical Center, New York, New York, United States
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 58
- Registration Number
- NCT00383149
- Locations
- 🇺🇸
Georgetn Univ Lombardi Can Ctr, Washington, District of Columbia, United States
🇺🇸Ellis Fischel Cancer Center, Columbia, Missouri, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 32
- Registration Number
- NCT00367250
- Locations
- 🇦🇹
Dept of Internal Medicine, Vienna, Austria
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
- Conditions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 38
- Registration Number
- NCT00362102
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
- Conditions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT00361244
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00350025
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00338039
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.